Molecular therapy for glaucoma: Ulinastatin (trade name: Miraclid, Ulinase, U-Tryp,Bikunin and Urinastatin), an urinary trypsin inhibitor used in the treatment of  acute/chronic pancreatitis, burns and others,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 15/January/2018, 11.36 pm

Ribonucleic acid-based therapy for Myocardial Infarction: LncRNA 015192 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 16/January/2019, 1.00 pm
January 15, 2019
Natural product-based anti-ageing and Lifespan extension therapy:  A pharmaceutical mixture encompassing Celecoxib and quercetin (CQ) increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene, 15/January/2019, 11.47 pm
January 15, 2019
Show all

Introduction: What they say

A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes Medical Institute, Bar Harbor, ME 04609, USA shows that “Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” This research paper was published, in the 9 February 2017 issue of the journal “Science” [One of the best research journals in “General science” with an I.F of 34.661], by Prof. Simon W. M. John and Pete A. Williams and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for glaucoma: Ulinastatin (trade name: Miraclid, Ulinase, U-Tryp,Bikunin and Urinastatin), an urinary trypsin inhibitor used in the treatment of  acute/chronic pancreatitis, burns and others,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) Glaucoma is a neurodegenerative disease; (2) more than 80 million people worldwide are affected by Glaucoma; (2) Glaucoma is the second leading cause of blindness; (3) Glucosma has no cure; (4) vision lost due to glaucoma is irreversible; (5) the global economic cost spent for Glaucoma treatment is enormous, there is an urgent need to find: (i) a way to induce regeneration of ganglion cells that were lost in Glaucoma; (ii) a cheaper alternative to the existing expensive anti-glaucoma drugs; (iii) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, Glaucoma permanently.


What is known?

Prof.Simon’s research team has recently shown that:(1) glaucoma-prone mice suffer from mitochondrial abnormalities, resulting in neuronal dysfunction; (2) NAD+ levels decrease with age; (3) administration of Niacin/Vitamin-B3 protects against glaucoma; (4) expression of Nmnat1, a key NAD+-producing enzyme, protects against glaucoma, suggesting that increasing the expression of Nmnat1 in glaucoma patients may alleviate glaucoma.


From research findings to Therapeutic opportunity:

This study suggests, for the first time, that Ulinastatin, by increasing the expression of their target gene, they may increase the expression of Nmnat1. Thereby, they may: (1) increase NAD+ levels; (2) decrease Intraocular pressure; (3) improve pressure-induced damage; (4) increase insulin sensitivity; and (5) alleviate glaucoma (Fig.1). Thus, Ulinastatin or its analogs either alone or in combination with other drugs, may be used to treat Glaucoma.

Figure 1. Mechanistic insights into how  Ulinastatin attenuates glaucoma. Brimonidine, by increasing the expression of its target gene, enhances NAD+ levels and improves glaucoma

Figure 2. Ulinastatin functions as an anti-glaucoma agent by increasing NAD+ levels



Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Ulinastatin increase the levels of NAD+?

Amount: $500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Molecular therapy for glaucoma: Ulinastatin (trade name: Miraclid, Ulinase, U-Tryp,Bikunin and Urinastatin), an urinary trypsin inhibitor used in the treatment of  acute/chronic pancreatitis, burns and others,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 15/January/2018, 11.36 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.